<DOC>
	<DOCNO>NCT00002443</DOCNO>
	<brief_summary>To compare effect CD4 count safety MK-639 ( indinavir , IDV ) AZT administer concomitantly MK-639 alone AZT alone HIV-1 seropositive patient .</brief_summary>
	<brief_title>The Safety Effectiveness MK-639 Zidovudine , Used Alone Together , HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize 1 3 group 12 month treatment . Group 1 receive MK-639 plus AZT . Group 2 receive MK-639 alone . Group 3 receive AZT alone . Safety tolerability assess incidence clinical laboratory adverse experience . Blood urine sample collect safety assessment determine CD4 cell count serum viral RNA level . If therapy MK-639 alone AZT find generally safe clinically efficacious , patient complete study opportunity continue extension study protocol treatment regimen include MK-639 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity . Average CD4 count 50 500 cells/mm3 base 2 separate prestudy determination least 1 week apart . Note : Patients know hemophilia may enrol discretion investigator . Prior Medication : Excluded : Any protease inhibitor . Significant prior use ( great 2 week ) nucleoside analogue . Chronic therapy active opportunistic infection . ( Allowed : Prophylaxis aerosolize pentamidine , trimethoprim/sulfamethoxazole , dapsone , topical antifungal , isoniazid ) . Investigational agent immunomodulators within 30 day prior study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute hepatitis . Lymphoma . Visceral Kaposi 's sarcoma . Invasive cervical cancer . Active infection . Concurrent Medication : Excluded : Anticipated immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1996</verification_date>
</DOC>